OTC Tylenol Sales Could Shrink By Half With Acetaminophen Dose Restriction

Johnson & Johnson could lose roughly $500 million in nonprescription Tylenol sales if FDA follows an advisory committee recommendation to switch 500-g tablets of acetaminophen to Rx status